0

Close
 
Upcoming Allied Market Research
2023
Infantile Spasms Therapeutics Market

Infantile Spasms Therapeutics Market

by Formulation Type (Solid, Liquid) and by Route of Administration (Oral, Parenteral): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A03359
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Infantile Spasms Therapeutics Market

Request Now !

An infantile spasm, also known as a West syndrome, is a rare seizure condition that occurs in an epilepsy syndrome of infancy and childhood. The initiation of infantile spasm usually occurs in the first year of life between four months and eight months of age. The condition is usually observed in 2% of childhood epilepsies and 25% of epilepsies that start in the first year of life. Almost 2,000-4,000 new cases are diagnosed in the U.S. annually. About 50%-70% of infantile spasms patients are affected by other types of seizures, whereas nearly 18%-50% develop either Lennox-Gastaut syndrome or other forms of symptomatic generalized epilepsy. There are only two FDA-approved medical treatment options available in the market-adrenocorticotropic hormone and vigabatrin.

The growing scientific advancements in the treatment for infantile spasms are the major factor that contributes to the market growth. For instance, due to advancements in technology, a seizure alert device has been developed that helps detect seizures and warns the physician through phone calls, alarms, or text messages. These advancements aid in early diagnosis by physicians, which increases the life expectancy of patients. Precise diagnosis of infantile spasms helps the physician make accurate decisions to prescribe an appropriate treatment regimen, thus improving the efficiency of the treatment.

These advanced technologies also help reduce the undiagnosed population, thereby enhancing the penetration rate of infantile spasm drugs. Furthermore, there are various awareness programs conducted by the government and private organizations to decrease the number of undiagnosed cases. Nevertheless, factors such as low success rate could hinder the growth of the infantile spasms therapeutics market.

The global infantile spasms therapeutics market is segmented based on formulation type, route of administration, and geography. Based on formulation type, the market is bifurcated into solid and liquid. Based on route of administration, the market is divided into oral and parenteral. Based on geography, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Valerion Therapeutics, Anavex Life Sciences Corp., GW Pharmaceuticals, plc., Mallinckrodt, H. Lundbeck A/S, ORPHELIA Pharma SA, INSYS Therapeutics, Inc., Retrophin, Inc., and CatalystPharma have also been provided in this report.

Key Benefits :

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global market.
  • This report entails a detailed quantitative analysis of the current market and estimations which helps identify prevailing market opportunities.
  • The projections in this report are made by analyzing the current trends and future market potential in terms of value.
  • Competitive intelligence helps understand the competitive scenario globally
  • An in-depth analysis of current research and clinical developments within the market has been provided with key market dynamic factors that helps understand the behavior of the market

 Infantile Spasms Therapeutics Market Report Highlights

Aspects Details
By Formulation Type
  • Solid
  • Liquid
By Route of Administration
  • Oral
  • Parenteral
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Taiwan, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Turkey, Rest of LAMEA)
Key Market Players ORPHELIA Pharma SA,, Mallinckrodt, H. Lundbeck A/S, INSYS Therapeutics, Inc., Anavex Life Sciences Corp., GW Pharmaceuticals, GW Pharmaceuticals, plc., Retrophin, Inc., Valerion Therapeutics, CatalystPharma
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: INFANTILE SPASMS THERAPEUTICS MARKET, BY FORMULATION TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Formulation Type

    • 4.2. Solid

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Liquid

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Route Of Administration

    • 5.2. Oral

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Parenteral

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: INFANTILE SPASMS THERAPEUTICS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Formulation Type

      • 6.2.3. Market Size and Forecast, By Route Of Administration

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Infantile Spasms Therapeutics Market

        • 6.2.5.1. Market Size and Forecast, By Formulation Type
        • 6.2.5.2. Market Size and Forecast, By Route Of Administration

      • 6.2.6. Canada Infantile Spasms Therapeutics Market

        • 6.2.6.1. Market Size and Forecast, By Formulation Type
        • 6.2.6.2. Market Size and Forecast, By Route Of Administration

      • 6.2.7. Mexico Infantile Spasms Therapeutics Market

        • 6.2.7.1. Market Size and Forecast, By Formulation Type
        • 6.2.7.2. Market Size and Forecast, By Route Of Administration

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Formulation Type

      • 6.3.3. Market Size and Forecast, By Route Of Administration

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Infantile Spasms Therapeutics Market

        • 6.3.5.1. Market Size and Forecast, By Formulation Type
        • 6.3.5.2. Market Size and Forecast, By Route Of Administration

      • 6.3.6. Germany Infantile Spasms Therapeutics Market

        • 6.3.6.1. Market Size and Forecast, By Formulation Type
        • 6.3.6.2. Market Size and Forecast, By Route Of Administration

      • 6.3.7. Italy Infantile Spasms Therapeutics Market

        • 6.3.7.1. Market Size and Forecast, By Formulation Type
        • 6.3.7.2. Market Size and Forecast, By Route Of Administration

      • 6.3.8. Spain Infantile Spasms Therapeutics Market

        • 6.3.8.1. Market Size and Forecast, By Formulation Type
        • 6.3.8.2. Market Size and Forecast, By Route Of Administration

      • 6.3.9. UK Infantile Spasms Therapeutics Market

        • 6.3.9.1. Market Size and Forecast, By Formulation Type
        • 6.3.9.2. Market Size and Forecast, By Route Of Administration

      • 6.3.10. Russia Infantile Spasms Therapeutics Market

        • 6.3.10.1. Market Size and Forecast, By Formulation Type
        • 6.3.10.2. Market Size and Forecast, By Route Of Administration

      • 6.3.11. Rest Of Europe Infantile Spasms Therapeutics Market

        • 6.3.11.1. Market Size and Forecast, By Formulation Type
        • 6.3.11.2. Market Size and Forecast, By Route Of Administration

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Formulation Type

      • 6.4.3. Market Size and Forecast, By Route Of Administration

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Infantile Spasms Therapeutics Market

        • 6.4.5.1. Market Size and Forecast, By Formulation Type
        • 6.4.5.2. Market Size and Forecast, By Route Of Administration

      • 6.4.6. Japan Infantile Spasms Therapeutics Market

        • 6.4.6.1. Market Size and Forecast, By Formulation Type
        • 6.4.6.2. Market Size and Forecast, By Route Of Administration

      • 6.4.7. India Infantile Spasms Therapeutics Market

        • 6.4.7.1. Market Size and Forecast, By Formulation Type
        • 6.4.7.2. Market Size and Forecast, By Route Of Administration

      • 6.4.8. South Korea Infantile Spasms Therapeutics Market

        • 6.4.8.1. Market Size and Forecast, By Formulation Type
        • 6.4.8.2. Market Size and Forecast, By Route Of Administration

      • 6.4.9. Australia Infantile Spasms Therapeutics Market

        • 6.4.9.1. Market Size and Forecast, By Formulation Type
        • 6.4.9.2. Market Size and Forecast, By Route Of Administration

      • 6.4.10. Thailand Infantile Spasms Therapeutics Market

        • 6.4.10.1. Market Size and Forecast, By Formulation Type
        • 6.4.10.2. Market Size and Forecast, By Route Of Administration

      • 6.4.11. Malaysia Infantile Spasms Therapeutics Market

        • 6.4.11.1. Market Size and Forecast, By Formulation Type
        • 6.4.11.2. Market Size and Forecast, By Route Of Administration

      • 6.4.12. Indonesia Infantile Spasms Therapeutics Market

        • 6.4.12.1. Market Size and Forecast, By Formulation Type
        • 6.4.12.2. Market Size and Forecast, By Route Of Administration

      • 6.4.13. Rest of Asia Pacific Infantile Spasms Therapeutics Market

        • 6.4.13.1. Market Size and Forecast, By Formulation Type
        • 6.4.13.2. Market Size and Forecast, By Route Of Administration

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Formulation Type

      • 6.5.3. Market Size and Forecast, By Route Of Administration

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Infantile Spasms Therapeutics Market

        • 6.5.5.1. Market Size and Forecast, By Formulation Type
        • 6.5.5.2. Market Size and Forecast, By Route Of Administration

      • 6.5.6. South Africa Infantile Spasms Therapeutics Market

        • 6.5.6.1. Market Size and Forecast, By Formulation Type
        • 6.5.6.2. Market Size and Forecast, By Route Of Administration

      • 6.5.7. Saudi Arabia Infantile Spasms Therapeutics Market

        • 6.5.7.1. Market Size and Forecast, By Formulation Type
        • 6.5.7.2. Market Size and Forecast, By Route Of Administration

      • 6.5.8. UAE Infantile Spasms Therapeutics Market

        • 6.5.8.1. Market Size and Forecast, By Formulation Type
        • 6.5.8.2. Market Size and Forecast, By Route Of Administration

      • 6.5.9. Argentina Infantile Spasms Therapeutics Market

        • 6.5.9.1. Market Size and Forecast, By Formulation Type
        • 6.5.9.2. Market Size and Forecast, By Route Of Administration

      • 6.5.10. Rest of LAMEA Infantile Spasms Therapeutics Market

        • 6.5.10.1. Market Size and Forecast, By Formulation Type
        • 6.5.10.2. Market Size and Forecast, By Route Of Administration

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Valerion Therapeutics

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Anavex Life Sciences Corp.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. GW Pharmaceuticals, Plc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Mallinckrodt, H. Lundbeck A/S

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. ORPHELIA Pharma SA,

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. INSYS Therapeutics, Inc.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Retrophin, Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. CatalystPharma

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. GW Pharmaceuticals

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET FOR SOLID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET FOR LIQUID, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET FOR PARENTERAL, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 11. U.S. INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 12. U.S. INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 13. CANADA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 14. CANADA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 15. MEXICO INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 16. MEXICO INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 17. EUROPE INFANTILE SPASMS THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 20. FRANCE INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 21. FRANCE INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 22. GERMANY INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 24. ITALY INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 25. ITALY INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 26. SPAIN INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 27. SPAIN INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 28. UK INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 29. UK INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 30. RUSSIA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 31. RUSSIA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 32. REST OF EUROPE INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 34. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 37. CHINA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 38. CHINA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 39. JAPAN INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 41. INDIA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 42. INDIA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 43. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 45. AUSTRALIA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 46. AUSTRALIA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 47. THAILAND INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 48. THAILAND INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 49. MALAYSIA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 50. MALAYSIA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 51. INDONESIA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 52. INDONESIA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 53. REST OF ASIA PACIFIC INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 55. LAMEA INFANTILE SPASMS THERAPEUTICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 58. BRAZIL INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 59. BRAZIL INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 60. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 62. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 63. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 64. UAE INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 65. UAE INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 66. ARGENTINA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 67. ARGENTINA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 68. REST OF LAMEA INFANTILE SPASMS THERAPEUTICS, BY FORMULATION TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA INFANTILE SPASMS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
  • TABLE 70. VALERION THERAPEUTICS: KEY EXECUTIVES
  • TABLE 71. VALERION THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 72. VALERION THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 73. VALERION THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 74. VALERION THERAPEUTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 75. ANAVEX LIFE SCIENCES CORP.: KEY EXECUTIVES
  • TABLE 76. ANAVEX LIFE SCIENCES CORP.: COMPANY SNAPSHOT
  • TABLE 77. ANAVEX LIFE SCIENCES CORP.: OPERATING SEGMENTS
  • TABLE 78. ANAVEX LIFE SCIENCES CORP.: PRODUCT PORTFOLIO
  • TABLE 79. ANAVEX LIFE SCIENCES CORP.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 80. GW PHARMACEUTICALS, PLC.: KEY EXECUTIVES
  • TABLE 81. GW PHARMACEUTICALS, PLC.: COMPANY SNAPSHOT
  • TABLE 82. GW PHARMACEUTICALS, PLC.: OPERATING SEGMENTS
  • TABLE 83. GW PHARMACEUTICALS, PLC.: PRODUCT PORTFOLIO
  • TABLE 84. GW PHARMACEUTICALS, PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 85. MALLINCKRODT, H. LUNDBECK A/S: KEY EXECUTIVES
  • TABLE 86. MALLINCKRODT, H. LUNDBECK A/S: COMPANY SNAPSHOT
  • TABLE 87. MALLINCKRODT, H. LUNDBECK A/S: OPERATING SEGMENTS
  • TABLE 88. MALLINCKRODT, H. LUNDBECK A/S: PRODUCT PORTFOLIO
  • TABLE 89. MALLINCKRODT, H. LUNDBECK A/S: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 90. ORPHELIA PHARMA SA,: KEY EXECUTIVES
  • TABLE 91. ORPHELIA PHARMA SA,: COMPANY SNAPSHOT
  • TABLE 92. ORPHELIA PHARMA SA,: OPERATING SEGMENTS
  • TABLE 93. ORPHELIA PHARMA SA,: PRODUCT PORTFOLIO
  • TABLE 94. ORPHELIA PHARMA SA,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 95. INSYS THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 96. INSYS THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 97. INSYS THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 98. INSYS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 99. INSYS THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 100. RETROPHIN, INC.: KEY EXECUTIVES
  • TABLE 101. RETROPHIN, INC.: COMPANY SNAPSHOT
  • TABLE 102. RETROPHIN, INC.: OPERATING SEGMENTS
  • TABLE 103. RETROPHIN, INC.: PRODUCT PORTFOLIO
  • TABLE 104. RETROPHIN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105. CATALYSTPHARMA: KEY EXECUTIVES
  • TABLE 106. CATALYSTPHARMA: COMPANY SNAPSHOT
  • TABLE 107. CATALYSTPHARMA: OPERATING SEGMENTS
  • TABLE 108. CATALYSTPHARMA: PRODUCT PORTFOLIO
  • TABLE 109. CATALYSTPHARMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 110. GW PHARMACEUTICALS: KEY EXECUTIVES
  • TABLE 111. GW PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 112. GW PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 113. GW PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 114. GW PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET
  • FIGURE 3. SEGMENTATION INFANTILE SPASMS THERAPEUTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN INFANTILE SPASMS THERAPEUTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALINFANTILE SPASMS THERAPEUTICS MARKET
  • FIGURE 11. INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION, BY BY FORMULATION TYPE
  • FIGURE 12. INFANTILE SPASMS THERAPEUTICS MARKET FOR SOLID, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. INFANTILE SPASMS THERAPEUTICS MARKET FOR LIQUID, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION, BY BY ROUTE OF ADMINISTRATION
  • FIGURE 15. INFANTILE SPASMS THERAPEUTICS MARKET FOR ORAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. INFANTILE SPASMS THERAPEUTICS MARKET FOR PARENTERAL, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 21. COMPETITIVE DASHBOARD
  • FIGURE 22. COMPETITIVE HEATMAP: INFANTILE SPASMS THERAPEUTICS MARKET
  • FIGURE 23. Top player positioning, 2022
  • FIGURE 24. VALERION THERAPEUTICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 25. VALERION THERAPEUTICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 26. VALERION THERAPEUTICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 27. ANAVEX LIFE SCIENCES CORP.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 28. ANAVEX LIFE SCIENCES CORP.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 29. ANAVEX LIFE SCIENCES CORP.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 30. GW PHARMACEUTICALS, PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 31. GW PHARMACEUTICALS, PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 32. GW PHARMACEUTICALS, PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 33. MALLINCKRODT, H. LUNDBECK A/S: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 34. MALLINCKRODT, H. LUNDBECK A/S: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 35. MALLINCKRODT, H. LUNDBECK A/S: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 36. ORPHELIA PHARMA SA,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 37. ORPHELIA PHARMA SA,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 38. ORPHELIA PHARMA SA,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 39. INSYS THERAPEUTICS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 40. INSYS THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 41. INSYS THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 42. RETROPHIN, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. RETROPHIN, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 44. RETROPHIN, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 45. CATALYSTPHARMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. CATALYSTPHARMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 47. CATALYSTPHARMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 48. GW PHARMACEUTICALS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. GW PHARMACEUTICALS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 50. GW PHARMACEUTICALS: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Infantile Spasms Therapeutics Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers